Pascual Jose Maria, Rodilla Enrique, Gonzalez Carmen, Pérez-Hoyos Santiago, Redon Josep
Hypertension Clinics, Sagunto Hospital, University of Valencia, Valencia, Spain.
Hypertension. 2005 Jun;45(6):1125-30. doi: 10.1161/01.HYP.0000167151.52825.11. Epub 2005 May 16.
The objective was to assess the temporal impact of factors related to the development of microalbuminuria during the follow-up of young adult normoalbuminurics with high-normal blood pressure or at stage 1 of essential hypertension. Prospective follow-up was conducted on 245 normoalbuminuric hypertensive subjects (mean age 40.9 years; 134 men; blood pressure 139.7/88.6 mm Hg; body mass index 28.5 kg/m2) never treated previously with antihypertensive drugs, with yearly urinary albumin excretion measurements, until the development of microalbuminuria. After enrollment, patients were placed on usual care including nonpharmacological treatment or with an antihypertensive drug regime to achieve a blood pressure of <135/85 mm Hg. Thirty subjects (12.2%) developed microalbuminuria after a mean follow-up of 29.9 months (range 12 to 144 months), 2.5 per 100 patients per year. Baseline urinary albumin excretion (hazard ratio, 1.07; P=0.006) and systolic blood pressure during the follow-up (hazard ratio, 1.03; P=0.008) were independent factors related to the follow-up urinary albumin excretion in a Cox proportional hazard model. A significant increase in the risk of developing microalbuminuria for urinary albumin excretion at baseline >15 mg per 24-hour systolic blood pressure >139 mm Hg and a positive trend in fasting glucose were observed in the univariate analyses. However, in the multivariate analysis, only the baseline urinary albumin excretion and the trend of fasting glucose were independently related to the risk of developing microalbuminuria. In mild hypertensives, the development of microalbuminuria was linked to insufficient blood pressure control and to a progressive increment of glucose values.
目的是评估在年轻的正常白蛋白尿、血压高正常或原发性高血压1期患者随访期间,与微量白蛋白尿发生相关因素的时间影响。对245例从未接受过抗高血压药物治疗的正常白蛋白尿高血压患者(平均年龄40.9岁;134例男性;血压139.7/88.6 mmHg;体重指数28.5 kg/m²)进行前瞻性随访,每年测量尿白蛋白排泄量,直至微量白蛋白尿发生。入组后,患者接受包括非药物治疗的常规护理或采用抗高血压药物治疗方案,以使血压<135/85 mmHg。30例患者(12.2%)在平均随访29.9个月(范围12至144个月)后发生微量白蛋白尿,每年每100例患者中有2.5例。在Cox比例风险模型中,基线尿白蛋白排泄量(风险比,1.07;P=0.006)和随访期间的收缩压(风险比,1.03;P=0.008)是与随访尿白蛋白排泄相关的独立因素。单因素分析中观察到,基线时24小时尿白蛋白排泄量>15 mg、收缩压>139 mmHg时发生微量白蛋白尿的风险显著增加,空腹血糖呈阳性趋势。然而,多因素分析中,只有基线尿白蛋白排泄量和空腹血糖趋势与发生微量白蛋白尿的风险独立相关。在轻度高血压患者中,微量白蛋白尿的发生与血压控制不足及血糖值的逐渐升高有关。
Nephrol Dial Transplant. 2007-3
Front Cardiovasc Med. 2022-8-10
Front Cardiovasc Med. 2022-3-10
Ther Clin Risk Manag. 2015-10-5
J Clin Hypertens (Greenwich). 2010-8
Am J Kidney Dis. 2010-11